Less than a week after announcing it had a new CEO, privately held Creyon Bio Inc. began a licensing and research partnership with Eli Lilly and Co. Creyon is getting $13 million up front and could bring in more than $1 billion in milestone payments. The two plan to find, develop and commercialize RNA-targeted oligonucleotide treatments for a range of diseases. Read More
PARP inhibitors have been approved for the treatment of several cancers, including ovarian, breast, pancreatic and prostate cancers with BRCA mutations or other homologous recombination repair deficiencies (HRD). However, their therapeutic potential is limited by challenges such as hematologic toxicity and lack of target selectivity. Read More
Odylia Therapeutics Inc. has announced it is working under a codevelopment partnership with the NPHP1 Family Foundation to create an AAV-based gene replacement therapy for retinal dystrophy caused by mutations in the NPHP1 (nephrocystin-1) gene. Read More
Alchemab Therapeutics Ltd. has entered into a licensing agreement with Eli Lilly and Co. for ATLX-1282, Alchemab’s first-in-class IND-ready program targeting a novel receptor and mechanism for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Read More
Yuhan Corp. has disclosed mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer. Read More
Aiming to develop a systemic therapy for advanced refractory cancers, researchers have designed a novel oncolytic adenovirus that selectively targets and kills cancer cells expressing mesothelin. Read More
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. reported the discovery of SHR-3591, an orally bioavailable AR proteolysis targeting chimera (PROTAC) designed to treat prostate tumors. Read More
Triple-negative breast cancer is an especially challenging subtype characterized by the absence of key receptors, limiting the effectiveness of many standard breast cancer treatments. Read More
Nutshell Therapeutics Inc. has synthesized deuterated indolizine compounds acting as cellular tumor antigen p53 (TP53) (Y220C mutant) reactivators reported to be useful for the treatment of cancer. Read More
Protein phosphatase 2A (PP2A) is a key serine/threonine phosphatase that controls various signaling pathways and influences cancer development and treatment outcomes. Read More
Jiangsu Simcere Pharmaceutical Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker reported to be useful for the treatment of cancer, neurodegeneration, infections, autoimmune and inflammatory disorders. Read More
Seaport Therapeutics Inc. has divulged lipid prodrugs of bromolysergide reported to be useful for the treatment of cluster headache and mood disorder. Read More
Prostate cancer remains a significant health concern for men globally, and the search for effective and targeted therapies continues. In a recent study, researchers from Guizhou Medical University identified a new class of 4-trifluoromethylquinoline derivatives that demonstrated potent anti-prostate cancer activity by inhibiting the serum/glucocorticoid-regulated kinase 1 (SGK1). Read More
Scientists at University of Connecticut and University of Iowa have described phosphonamidate prodrugs reported to be useful for the treatment of cancer. Read More
